JP2015522573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522573A5 JP2015522573A5 JP2015519000A JP2015519000A JP2015522573A5 JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5 JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition according
- composition
- glp
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535 | 2012-07-01 | ||
| EP12174535.0 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781.6 | 2012-10-01 | ||
| US61/708,162 | 2012-10-01 | ||
| EP12186781 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522573A JP2015522573A (ja) | 2015-08-06 |
| JP2015522573A5 true JP2015522573A5 (enExample) | 2016-03-10 |
| JP6059802B2 JP6059802B2 (ja) | 2017-01-11 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519000A Active JP6059802B2 (ja) | 2012-07-01 | 2013-06-21 | 長時間作用型ｇｌｐ−１ペプチドの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (enExample) |
| EP (3) | EP2866825B1 (enExample) |
| JP (1) | JP6059802B2 (enExample) |
| AU (3) | AU2013286177B2 (enExample) |
| BR (1) | BR112014032938A2 (enExample) |
| CA (1) | CA2877056A1 (enExample) |
| DK (1) | DK2866825T3 (enExample) |
| ES (2) | ES3041720T3 (enExample) |
| HR (2) | HRP20251088T1 (enExample) |
| HU (2) | HUE049152T2 (enExample) |
| MX (3) | MX376058B (enExample) |
| PL (2) | PL3689365T3 (enExample) |
| PT (1) | PT2866825T (enExample) |
| RS (2) | RS60432B1 (enExample) |
| RU (2) | RU2657573C2 (enExample) |
| SI (1) | SI2866825T1 (enExample) |
| WO (1) | WO2014005858A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX345501B (es) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
| KR101972836B1 (ko) | 2011-04-12 | 2019-04-29 | 노보 노르디스크 에이/에스 | 이중 아실화된 ｇｌｐ-1 유도체 |
| EP2827885B1 (en) | 2012-03-22 | 2018-08-15 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| HRP20251088T1 (hr) | 2012-07-01 | 2025-11-07 | Novo Nordisk A/S | Upotreba dugodjelujućih peptida glp‑1 |
| SMT201800492T1 (it) | 2013-05-02 | 2018-11-09 | Novo Nordisk As | Dosaggio orale di composti di glp-1 |
| US10543843B2 (en) * | 2014-10-16 | 2020-01-28 | Yanmar Co., Ltd. | Work vehicle |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| IL322969A (en) * | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| JP2022521551A (ja) * | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CN114728042A (zh) * | 2019-11-06 | 2022-07-08 | 诺和诺德股份有限公司 | 用于痴呆的glp-1受体激动剂 |
| CN119060162A (zh) * | 2019-12-30 | 2024-12-03 | 甘李药业股份有限公司 | 长效glp-1化合物 |
| TW202228762A (zh) | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| BR112022013795A2 (pt) | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| EP4359074A4 (en) * | 2021-06-24 | 2025-06-04 | Gila Therapeutics, Inc. | METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| LT4408840T (lt) | 2021-09-27 | 2025-10-10 | Benzimidazolo karboksilinės rūgštys kaip glp-1r agonistai | |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023086499A1 (en) | 2021-11-10 | 2023-05-19 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| AU2023415591A1 (en) | 2022-12-30 | 2025-08-14 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| AU2024299322A1 (en) | 2023-07-24 | 2026-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| KR102930984B1 (ko) * | 2024-01-29 | 2026-02-25 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2026046328A1 (en) * | 2024-08-30 | 2026-03-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Dosing regimen of glp-1 conjugates |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| EP1412384B1 (en) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| DK3300721T4 (da) | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| CN106137952B (zh) | 2004-11-12 | 2020-11-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR20150042304A (ko) | 2006-04-14 | 2015-04-20 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| US20100047762A1 (en) | 2007-03-20 | 2010-02-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| EP2164466A1 (en) | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| CN104327182B (zh) | 2009-12-16 | 2020-04-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| KR101927068B1 (ko) * | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| MX345501B (es) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| CN103906528A (zh) | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| HRP20251088T1 (hr) | 2012-07-01 | 2025-11-07 | Novo Nordisk A/S | Upotreba dugodjelujućih peptida glp‑1 |
-
2013
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522573A5 (enExample) | ||
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| JP2015110588A5 (enExample) | ||
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (enExample) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| JP2015501832A5 (enExample) | ||
| WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| UA118656C2 (uk) | Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. | |
| JP2018043942A5 (enExample) | ||
| Sheehy | Ketamine/morphine | |
| Carman | Ferric carboxymaltose |